Larimar Therapeutics

LRMR56

High Growth

$6.25arrow_drop_up1.97%$0.12

High Growth

LRMR56

$6.25

arrow_drop_up1.97%$0.12

High Growth

Performance History

Key Stats
Open	$6.13
Prev. Close	$6.13
EPS	-1.15
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	6.13	6.30
52 Week Range	2.18	13.68

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.15

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Larimar Therapeutics (LRMR)

Larimar Therapeutics, Inc. (LRMR) is a biopharmaceutical company that focuses on developing innovative treatments for rare genetic diseases. The company is dedicated to improving the lives of patients with these diseases by discovering and developing new therapies. Larimar Therapeutics is known for its commitment to research and its strategic partnerships with leading academic institutions and pharmaceutical companies. The company's stock price history has shown steady growth over the years, reflecting the market's confidence in its potential. Investors have been attracted to LRMR due to its promising pipeline of drug candidates that target a range of genetic diseases.

One of the key strengths of Larimar Therapeutics is its smart analysis capabilities. The company leverages advanced data analytics and machine learning algorithms to evaluate the efficacy and safety of its drug candidates. This allows Larimar Therapeutics to make informed decisions about which therapies to advance to clinical trials and ultimately to market. By using a combination of scientific expertise and cutting-edge technology, the company is able to optimize its drug development process and increase the likelihood of successful outcomes. This smart analysis approach sets Larimar Therapeutics apart from its competitors and positions it as a leader in the field of rare genetic disease treatment.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Carole S. Ben-Maimon M.D.
Headquarters: Bala Cynwyd
Employees: 26
Exchange: NASDAQ

Keep an eye on Larimar Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Larimar Therapeutics's (LRMR) price per share?

The current price per share for Larimar Therapeutics (LRMR) is $6.25. The stock has seen a price change of $0.12 recently, indicating a 1.97% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Larimar Therapeutics (LRMR)?

For Larimar Therapeutics (LRMR), the 52-week high is $13.68, which is 118.84% from the current price. The 52-week low is $2.18, the current price is 186.74% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Larimar Therapeutics (LRMR) a growth stock?

Larimar Therapeutics (LRMR) has shown an average price growth of -7.23% over the past three years. It has received a score of 63 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Larimar Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Larimar Therapeutics (LRMR) stock price performance year to date (YTD)?

As of the latest data, Larimar Therapeutics (LRMR) has a year-to-date price change of 22.33%. Over the past month, the stock has experienced a price change of -16.99%. Over the last three months, the change has been -23.21%. Over the past six months, the figure is -20.77%.

help

Is Larimar Therapeutics (LRMR) a profitable company?

Larimar Therapeutics (LRMR) has a net income of -$36.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$41.76M. Furthermore, the EBITDA is -$73.44M.

help

What is the market capitalization of Larimar Therapeutics (LRMR)?

Larimar Therapeutics (LRMR) has a market capitalization of $391.13M. The average daily trading volume is 6.26, indicating the stock's liquidity and investor engagement.